PersonalizedMedicine

Our mission is to accelerate the use of personalized medicine in the clinical setting to improve patient care. Use #PMConf for our Personalized Medicine Conf.

[PersonalizedMedicine @PartnersPersMed]

Another great #PMConf for the books – thanks to all who joined us! We’ll see you next year!

[PersonalizedMedicine @PartnersPersMed]

Key themes: Prevention, physician ed, pricing, partnerships, protocols & of course – patients – are future of #personalizedmedicine #PMConf

[PersonalizedMedicine @PartnersPersMed]

.@harvardmed Kucherlapati sums up 2015 #PMConf: It's not whether #personalizedmedicine is here to stay but how fast it’s being implemented

[PersonalizedMedicine @PartnersPersMed]

.@AstraZenecaUS Hudson: We need to look beyond disease states, see patients as partners not data points. #PMConf

[Intermountain Cancer @intermtncancer]

PH: It's about breakthrough science and collaboration rather than who can get there first. @AstraZenecaUS #PMConf

[PersonalizedMedicine @PartnersPersMed]

Paul Hudson @AstraZenecaUS: Testing for #genetic mutations in #cancer can be as easy as testing glucose levels today #PMConf

[AstraZenecaUS @AstraZenecaUS]

“We need to move from treating the disease, to treating the mutation, to treating the individual” Paul Hudson #PMconf

[PersonalizedMedicine @PartnersPersMed]

.@AstraZenecaUS Hudson: Still only 500 treatments for 7,000 known diseases. Continued collab. needed to reach more patients #PMConf

[Intermountain Cancer @intermtncancer]

MP: Overall, we are here to impact the care of the patient and to help them fight cancer. #PMConf

[PersonalizedMedicine @PartnersPersMed]

Thank you! We're looking forward to his keynote. #PMConf https://t.co/B4LgslZULi

[AstraZenecaUS @AstraZenecaUS]

Great panel discussion @ #PMconf. AZ US Pres. Paul Hudson about to address audience on redefining the value of care w/ #personalizedmedicine

[PersonalizedMedicine @PartnersPersMed]

Yancopoulos: Cutting R&D is short-sighted. Need to elevate long-term view, have strong research, innovation, investment, prevention #PMConf

[PersonalizedMedicine @PartnersPersMed]

.@PMCAmy from audience: Sometimes payer responses to Dx are irresponsible, arbitrary. Need to join together, come up w/ solutions #PMConf

[Angeliki Pantazi @apantaz]

Yancopoulos @regeneron on importance of basic research that precedes translational achievements #PMConf

[PersonalizedMedicine @PartnersPersMed]

Ability to send samples btwn countries instead of sequencing in country, sending data is big biz dev opp @SiemensHealth Reitermann #PMConf

[PersonalizedMedicine @PartnersPersMed]

.@regeneron @GeisingerHealth study #genetics info w/ 2 separate but complimentary goals: new therapies, better decision making #PMConf

[PersonalizedMedicine @PartnersPersMed]

.@SiemensHealth Michael Reitermann shares stats on errors in diagnostics from recent @theIOM report https://t.co/thjn1s3Ipr #PMConf

[PersonalizedMedicine @PartnersPersMed]

.@NofOne is an example says Cournoyer! She was told there's no such thing as a molecular decision support company
https://t.co/KgEowAHab0

[Samantha Baxter @SamBaxterCGC]

"If it's easy then someone is already working on it. It's the hard stuff that has the biggest impact and payoff" @MichaelPellini #pmconf

[PersonalizedMedicine @PartnersPersMed]

.@FoundationATCG Pellini: There's no "if" only "when & how" #genetic testing will become the norm, payers will cover Dx #PMConf

[Intermountain Cancer @intermtncancer]

Michael Reitermann: We're somewhere between evolution and revolution of patient care. Patient is number one. #PMConf #genomics